Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Dyskeratosis Congenita: early-phase trial registry

5 of 8 indexed Dyskeratosis Congenita trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · 5 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Dyskeratosis Congenita: 8 US clinical trials tracked, 5 recruiting.

Dyskeratosis Congenita is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Masonic Cancer Center, University of Minnesota, running 2 of these trials.

Enrollment posture brief

Registry condition dyskeratosis-congenita

OPEN 5 | RECR 63% | LATE 0 | EARLY 4 | RANK #2176 | SPON 2

Nearest open-share peer: Adolescent (63% recruiting · 16 trials)

Activity, Motor75%Dyskeratosis Congenita (this)63%Achalasia50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%
Open-enrollment share among volume-matched conditions near Dyskeratosis Congenita

Dyskeratosis Congenita lists 5 open slots (63% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Dyskeratosis Congenita on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Dyskeratosis Congenita is recruiting above its size-band peers.

    5 of 8 indexed trials (62.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Dyskeratosis Congenita research.

    Masonic Cancer Center, University of Minnesota accounts for 2 of 8 trials (25%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Dyskeratosis Congenita trials plan to enrol fewer than 100 people.

    Median target enrolment is 53 among the 8 trials that report a genuine target (sentinel values excluded). 6 of those (75%) plan for fewer than 100 participants.

  4. Dyskeratosis Congenita splits between interventional and observational designs.

    5 interventional and 3 observational studies make up this index (62.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 23

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 3

Named interventions

Most-linked intervention names on Dyskeratosis Congenita records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Fludarabine Drug
3 trials
Alemtuzumab Drug
2 trials
Cyclophosphamide Drug
2 trials
Stem Cell Transplant Biological
1 trials
Cyclosporins Drug
1 trials
alemtuzumab Biological
1 trials
Donor mobilized PBSC infusion Device
1 trials
Methylprednisolone (MP) Drug
1 trials

US sites by state

Facility locations filed on Dyskeratosis Congenita trials. A trial with sites in several states counts in each.

Maryland 3 trials
Minnesota 2 trials
Massachusetts 2 trials
Wisconsin 1 trials
Washington 1 trials
Texas 1 trials
Tennessee 1 trials
Pennsylvania 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Dyskeratosis Congenita page

8 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Dyskeratosis Congenita condition card totals 8 registered trials; most-linked intervention Fludarabine; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.